BidaskClub downgraded shares of bluebird bio (NASDAQ:BLUE) from a strong-buy rating to a buy rating in a report released on Friday, March 16th.
Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald reiterated a sell rating and issued a $113.00 price objective (down from $122.00) on shares of bluebird bio in a research note on Wednesday, February 21st. Maxim Group increased their price target on bluebird bio from $170.00 to $200.00 and gave the stock a buy rating in a research report on Thursday, November 30th. Barclays restated an overweight rating and set a $209.00 price target (up from $162.00) on shares of bluebird bio in a research report on Wednesday, December 13th. Zacks Investment Research lowered bluebird bio from a hold rating to a sell rating in a research report on Monday, February 26th. Finally, Jefferies Group upgraded bluebird bio from a hold rating to a buy rating and increased their price target for the stock from $130.00 to $211.00 in a research report on Monday, December 11th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio has a consensus rating of Hold and an average price target of $195.20.
Shares of NASDAQ BLUE traded down $7.45 during trading hours on Friday, hitting $162.70. 1,088,977 shares of the company’s stock were exchanged, compared to its average volume of 934,688. The stock has a market capitalization of $8,504.69, a PE ratio of -21.10 and a beta of 2.16. bluebird bio has a 1-year low of $74.45 and a 1-year high of $236.17.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.84). The firm had revenue of $4.17 million during the quarter, compared to analyst estimates of $7.11 million. bluebird bio had a negative net margin of 947.42% and a negative return on equity of 28.09%. The company’s revenue was up 169.0% on a year-over-year basis. During the same period last year, the company earned ($1.88) EPS. sell-side analysts predict that bluebird bio will post -8.39 earnings per share for the current fiscal year.
In related news, insider Philip D. Gregory sold 2,250 shares of bluebird bio stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $200.00, for a total transaction of $450,000.00. Following the completion of the transaction, the insider now owns 32,522 shares in the company, valued at $6,504,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Susanna Gatti High sold 17,262 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total transaction of $3,381,798.42. Following the sale, the chief operating officer now owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The disclosure for this sale can be found here. Insiders sold a total of 80,034 shares of company stock valued at $15,122,163 in the last 90 days. 3.90% of the stock is owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the business. Xact Kapitalforvaltning AB acquired a new stake in bluebird bio during the fourth quarter worth approximately $807,000. MetLife Investment Advisors LLC acquired a new stake in bluebird bio during the fourth quarter worth approximately $3,935,000. Redmile Group LLC acquired a new stake in bluebird bio during the fourth quarter worth approximately $46,270,000. Element Capital Management LLC acquired a new stake in bluebird bio during the fourth quarter worth approximately $23,592,000. Finally, Kazazian Asset Management LLC lifted its position in bluebird bio by 11.6% during the fourth quarter. Kazazian Asset Management LLC now owns 4,555 shares of the biotechnology company’s stock worth $811,000 after acquiring an additional 472 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/bluebird-bio-blue-lowered-to-buy-at-bidaskclub.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.